MarketCap
Facebook
X
TelegramAnnual report 2025
added 02-26-2026
Akebia Therapeutics Net Income 2011-2026 | AKBA
Net profit is a financial indicator that reflects the remaining amount of money after deducting all expenses and taxes from the company’s total income over a certain period of time. It is one of the key indicators of a company’s financial stability and success.
Net profit is the portion of total profit remaining after taxes and depreciation have been deducted.[1]
It is the result of a company’s operations and reflects its efficiency in managing resources, controlling expenses, and generating income. It includes all operating revenues and expenses, such as sales of goods or services, production costs, administrative expenses, taxes, and other financial metrics.
The calculation of net profit includes the deduction of all necessary expenses such as employee salaries, rent, utilities, taxes, and other mandatory payments. After all these expenses are deducted from the total income, the remaining amount is considered the company’s net profit.
Net profit is an important indicator of a company’s financial health, as it reflects its ability to generate earnings and manage its finances. High net profit indicates business success, competitiveness, and efficiency in resource utilization. It also allows a company to invest in its development, pay dividends to shareholders, or create reserve funds for unforeseen situations.
It serves as a basis for calculating other financial indicators, such as return on sales, return on assets, or return on equity. It is also used to assess the performance of management and make decisions regarding the future development of the company.
However, it should be noted that net profit can be affected by various factors, such as economic conditions, changes in legislation, market competition, and other external influences. Therefore, companies must be prepared for possible changes and take measures to ensure the stability of their financial results.
Annual Net Income Akebia Therapeutics
| 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| -5.34 M | -69.4 M | -51.9 M | -94.2 M | -282 M | -385 M | -280 M | -144 M | -76.9 M | -136 M | -60.7 M | -37 M | -13.2 M | -8.2 M | - |
All numbers in USD currency
Indicator range from annual reports
| Maximum | Minimum | Average |
|---|---|---|
| -5.34 M | -385 M | -117 M |
Quarterly Net Income Akebia Therapeutics
| 2025-Q3 | 2025-Q2 | 2025-Q1 | 2024-Q4 | 2024-Q3 | 2024-Q2 | 2024-Q1 | 2023-Q4 | 2023-Q3 | 2023-Q2 | 2023-Q1 | 2022-Q4 | 2022-Q3 | 2022-Q2 | 2022-Q1 | 2021-Q4 | 2021-Q3 | 2021-Q2 | 2021-Q1 | 2020-Q4 | 2020-Q3 | 2020-Q2 | 2020-Q1 | 2019-Q4 | 2019-Q3 | 2019-Q2 | 2019-Q1 | 2018-Q4 | 2018-Q3 | 2018-Q2 | 2018-Q1 | 2017-Q4 | 2017-Q3 | 2017-Q2 | 2017-Q1 | 2016-Q4 | 2016-Q3 | 2016-Q2 | 2016-Q1 | 2015-Q4 | 2015-Q3 | 2015-Q2 | 2015-Q1 | 2014-Q4 | 2014-Q3 | 2014-Q2 | 2014-Q1 | 2013-Q4 | 2013-Q3 | 2013-Q2 | 2013-Q1 | 2012-Q4 | 2012-Q3 | 2012-Q2 | 2012-Q1 | 2011-Q4 | 2011-Q3 | 2011-Q2 | 2011-Q1 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 540 K | 247 K | 6.11 M | - | -20 M | -8.58 M | -18 M | - | -14.5 M | -11.2 M | -26.2 M | - | -54.1 M | 29.4 M | -62.4 M | - | -59.5 M | -83 M | -69.6 M | -87 M | -60 M | -176 M | -60.7 M | -94.5 M | -54.6 M | -58.2 M | -72.4 M | -60.1 M | -26 M | -34.1 M | -60.1 M | 15.5 M | -23.1 M | -21.5 M | -44.5 M | -37.9 M | -36.3 M | -35.8 M | -25.8 M | -19.9 M | -19.5 M | -10.7 M | -10.7 M | -10.4 M | -9.35 M | -7.62 M | -9.7 M | -5.95 M | -3.77 M | -2.83 M | -621 K | - | - | - | - | - | - | - | - |
All numbers in USD currency
Indicator range from quarterly reporting
| Maximum | Minimum | Average |
|---|---|---|
| 29.4 M | -176 M | -33.1 M |
References
- Bhamornsiri, S., & Wiggins, C. (2001). Comprehensive income disclosures. The CPA Journal, 71(10), 54.
Net Income of other stocks in the Biotechnology industry
| Issuer | Net Income | Price | % 24h | Market Cap | Country | |
|---|---|---|---|---|---|---|
 |
MorphoSys AG
MOR
|
-514 M | - | 2.43 % | $ 254 M |  Germany |
 |
Nanobiotix S.A.
NBTX
|
-47 M | $ 30.34 | -0.82 % | $ 286 B |  France |
 |
I-Mab
IMAB
|
-1.47 B | - | - | $ 866 M |  China |
 |
AlloVir
ALVR
|
-43.4 M | - | 4.14 % | $ 49.1 M |  USA |
 |
Applied Molecular Transport
AMTI
|
-126 M | - | - | $ 10.1 M | USA |
 |
Alexion Pharmaceuticals, Inc.
ALXN
|
603 M | - | - | $ 40.3 B | USA |
 |
Genfit SA
GNFT
|
67.3 M | - | 2.54 % | $ 160 B | France |
 |
Biophytis SA
BPTS
|
-31.2 M | - | -13.47 % | $ 169 M | France |
 |
Applied Therapeutics
APLT
|
-120 M | - | - | $ 8.42 M | USA |
 |
BioNTech SE
BNTX
|
10.3 B | $ 95.5 | 3.83 % | $ 27.2 B | Germany |
 |
EyeGate Pharmaceuticals, Inc.
EYEG
|
-8.09 M | - | -1.52 % | $ 24.7 M | USA |
 |
Can-Fite BioPharma Ltd.
CANF
|
-9.83 M | $ 2.92 | -0.34 % | $ 6.35 B |  Israel |
 |
Midatech Pharma plc
MTP
|
-5.46 M | - | -18.52 % | $ 27.3 M |  Britain |
 |
Amphastar Pharmaceuticals
AMPH
|
98.1 M | $ 20.37 | -2.4 % | $ 952 M | USA |
 |
Acorda Therapeutics
ACOR
|
-253 M | - | -24.86 % | $ 820 K | USA |
 |
Институт стволовых клеток человека
ISKJ
|
72.9 M | - | - | - |  Russia |
 |
Adverum Biotechnologies
ADVM
|
-131 M | - | - | $ 86.2 M | USA |
 |
Advaxis
ADXS
|
-48.1 M | - | -9.65 % | $ 45.9 M | USA |
 |
Aeterna Zentaris
AEZS
|
-8.37 M | - | 5.93 % | $ 314 M |  Canada |
 |
AgeX Therapeutics
AGE
|
-19.2 M | - | -10.17 % | $ 12.2 K | USA |
 |
Celldex Therapeutics
CLDX
|
-259 M | $ 32.24 | -4.1 % | $ 2.14 B | USA |
 |
Aeglea BioTherapeutics
AGLE
|
-155 M | - | - | $ 1.01 B | USA |
 |
Applied Genetic Technologies Corporation
AGTC
|
-18.4 M | - | - | $ 26.5 M | USA |
 |
Allakos
ALLK
|
-186 M | - | - | $ 28.6 M | USA |
 |
Aptinyx
APTX
|
-64.8 M | - | -39.0 % | $ 4.57 M | USA |
 |
Aquestive Therapeutics
AQST
|
-83.8 M | $ 4.08 | -2.16 % | $ 436 M | USA |
 |
Aravive
ARAV
|
-76.3 M | - | -13.39 % | $ 1.45 M | USA |
 |
Arcutis Biotherapeutics
ARQT
|
-16.1 M | $ 24.21 | -1.47 % | $ 3.08 B | USA |
 |
AIkido Pharma
AIKI
|
-22.4 M | - | 1.93 % | $ 17.4 M | USA |
 |
Autolus Therapeutics plc
AUTL
|
-288 M | $ 1.49 | 1.36 % | $ 397 M | Britain |
 |
Aptose Biosciences
APTO
|
-25.5 M | - | -45.71 % | $ 1.2 M | Canada |
 |
Cidara Therapeutics
CDTX
|
-170 M | - | - | $ 1.41 B | USA |
 |
AVROBIO
AVRO
|
12.2 M | - | 1083.1 % | $ 745 M | USA |
 |
Ayala Pharmaceuticals
AYLA
|
-38 M | - | - | $ 7.46 M | Israel |
 |
Aytu BioScience
AYTU
|
-13.6 M | $ 2.55 | -0.78 % | $ 16 M | USA |
 |
InflaRx N.V.
IFRX
|
-45.6 M | $ 1.0 | -2.91 % | $ 152 M | Germany |
 |
AstraZeneca PLC
AZN
|
115 M | - | - | $ 96.9 B | Britain |
 |
Immutep Limited
IMMP
|
-29.9 M | $ 0.31 | -2.52 % | $ 1.08 B |  Australia |
 |
Akero Therapeutics
AKRO
|
-252 M | - | - | $ 3.67 B | USA |
 |
CureVac N.V.
CVAC
|
-412 M | - | - | $ 867 M | Germany |
 |
Brainstorm Cell Therapeutics
BCLI
|
-10.3 M | - | -2.5 % | $ 5.88 M | USA |
 |
BeiGene, Ltd.
BGNE
|
287 M | - | 0.49 % | $ 251 B |  Cayman-islands |
 |
Akouos
AKUS
|
-86.7 M | - | 0.23 % | $ 488 M | USA |
 |
Akari Therapeutics, Plc
AKTX
|
-17.3 M | $ 3.83 | -2.3 % | $ 258 B | Britain |
 |
Allena Pharmaceuticals
ALNA
|
-48.7 M | - | 3.16 % | $ 1.9 M | USA |
 |
Evogene Ltd.
EVGN
|
-30.4 M | $ 0.81 | -1.16 % | $ 27.9 M | Israel |
 |
Baudax Bio
BXRX
|
-58.8 M | - | 0.59 % | $ 63 K | USA |
 |
Alpine Immune Sciences
ALPN
|
-57.8 M | - | - | $ 2.17 B | USA |
 |
Cabaletta Bio
CABA
|
-168 M | $ 3.13 | -1.26 % | $ 315 M | USA |